SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)
SAB Biotherapeutics (SABS) reported Preferred Stock Liabilities of $116.2 million for Q3 2021, up 13.66% quarter-over-quarter from $102.2 million in Q2 2021.
SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021) Analysis & Trends
SAB Biotherapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $116.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 116.15 Mn |
| Jun 30, 2021 | 102.19 Mn |
| Mar 31, 2021 | 104.39 Mn |